Petri is a consultant for TechLab Inc., a company that produces diagnostic tests for C. difficile. Petri and Tyus are also ...

LPOXY’s plan is to take Sidiprev into a phase 2 study in hospitalized patients with Clostridioides difficile infection. Known as one of the superbugs that resists most antibiotics, C.

How does recurrent C difficile infection impact health care resources utilization and other medical costs? What are the ways in which recurrent C difficile infection can adversely impact a patient ...

Pfizer has been working on a potential vaccine for C. diff, but its first attempt missed ... updated formulation through mid-stage clinical testing. In the phase 3 ECOSPOR trial, patients who ...

Roche has obtained U.S. government green lights allowing its point-of-care testing system to be used to screen for multiple ...

Patients suffering from a recurrent infection with the C difficile bacteria have benefited from a microbiome treatment from Rebiotix. The results from the open label phase 2 trial confirm that ...

Pharmaceutical Innovations, Collaborative Research Initiatives, and Increased Awareness Driving Clostridium Difficile Infection Treatment Market GrowthRockville, MD, Jan. 23, 2025 (GLOBE NEWSWIRE) -- ...